Skip to main content
TipRanks
Go Ultimate75% OFF

Ligand Pharma (LGND) Ratios

860 Followers

Ligand Pharma Ratios

LGND's free cash flow for Q3 2026 was $-27.73M. For the 2026 fiscal year, LGND's free cash flow was decreased by $-142.00K and operating cash flow was $-27.59M. See a summary of the company’s cash flow.

Financial ratios
RatiosDec 25Dec 24Dec 23Dec 22Dec 21
Liquidity Ratios
Current Ratio22.238.9314.152.6711.15
Quick Ratio21.988.5512.722.5310.50
Cash Ratio4.671.951.370.460.47
Solvency Ratio0.290.281.030.060.23
Operating Cash Flow Ratio1.322.612.951.401.89
Short-Term Operating Cash Flow Coverage0.000.000.001.800.00
Net Current Asset Value$ 288.85M$ 220.22M$ 151.13M$ 98.42M$ -11.68M
Leverage Ratios
Debt-to-Assets Ratio0.290.010.010.120.25
Debt-to-Equity Ratio0.440.010.010.150.40
Debt-to-Capital Ratio0.310.010.010.130.28
Long-Term Debt-to-Capital Ratio0.300.000.000.000.28
Financial Leverage Ratio1.531.131.121.281.58
Debt Service Coverage Ratio33.5611.28138.710.517.49
Interest Coverage Ratio10.01-7.4418.201.695.29
Debt to Market Cap0.120.000.000.070.12
Interest Debt Per Share23.590.550.395.3120.69
Net Debt to EBITDA1.43-1.60-0.170.532.14
Profitability Margins
Gross Profit Margin97.54%93.37%73.31%73.08%74.26%
EBIT Margin59.29%3.32%48.98%19.27%38.02%
EBITDA Margin71.89%24.41%76.79%41.38%59.11%
Operating Profit Margin17.61%-13.53%9.09%1.55%42.99%
Pretax Profit Margin59.29%1.51%48.48%18.35%29.89%
Net Profit Margin46.42%-2.41%39.72%-17.00%23.66%
Continuous Operations Profit Margin46.42%-2.41%40.98%-2.66%31.61%
Net Income Per EBT78.29%-160.13%81.93%-92.64%79.13%
EBT Per EBIT336.79%-11.14%533.08%1185.74%69.53%
Return on Assets (ROA)7.97%-0.43%6.63%-4.37%4.40%
Return on Equity (ROE)12.23%-0.49%7.44%-5.58%6.96%
Return on Capital Employed (ROCE)3.10%-2.50%1.55%0.46%8.27%
Return on Invested Capital (ROIC)2.42%4.00%1.31%-0.06%8.26%
Return on Tangible Assets12.00%-0.71%13.57%-10.96%7.10%
Earnings Yield3.40%-0.21%4.22%-2.96%2.22%
Efficiency Ratios
Receivables Turnover4.393.943.345.602.64
Payables Turnover2.032.1214.449.957.40
Inventory Turnover0.720.781.463.972.28
Fixed Asset Turnover24.846.745.247.147.41
Asset Turnover0.170.180.170.260.19
Working Capital Turnover Ratio0.490.650.680.670.59
Cash Conversion Cycle409.36385.42333.61120.35249.57
Days of Sales Outstanding83.1292.70109.2765.17138.49
Days of Inventory Outstanding505.65465.20249.6191.85160.42
Days of Payables Outstanding179.41172.4825.2736.6749.33
Operating Cycle588.77557.90358.88157.02298.90
Cash Flow Ratios
Operating Cash Flow Per Share2.555.312.878.174.74
Free Cash Flow Per Share2.534.23-0.257.114.21
Dividend Paid and CapEx Coverage Ratio109.204.940.927.698.99
Capital Expenditure Coverage Ratio109.204.940.927.698.99
Operating Cash Flow Coverage Ratio0.1113.668.041.570.24
Operating Cash Flow to Sales Ratio0.180.580.380.700.33
Free Cash Flow Yield1.34%3.95%-0.35%10.64%2.73%
Valuation Ratios
Price-to-Earnings (P/E) Ratio29.36-487.0523.69-33.7844.96
Price-to-Sales (P/S) Ratio13.6411.739.415.7410.63
Price-to-Book (P/B) Ratio3.592.361.761.893.13
Price-to-Free Cash Flow (P/FCF) Ratio74.7625.32-289.199.4036.68
Price-to-Operating Cash Flow Ratio74.0720.1924.928.1732.60
Price-to-Earnings Growth (PEG) Ratio-0.014.54-0.090.21-0.02
Enterprise Value Multiple20.4146.4412.0914.4020.13
Enterprise Value3.93B1.89B1.22B1.17B2.87B
EV to EBITDA20.4146.4412.0914.4020.13
EV to Sales14.6711.349.285.9611.90
EV to Free Cash Flow80.4124.48-285.269.7541.03
EV to Operating Cash Flow79.6819.5224.588.4836.47
Tangible Book Value Per Share25.5125.0717.228.2519.76
Shareholders’ Equity Per Share52.6045.4040.5235.4249.38
Tax and Other Ratios
Effective Tax Rate0.222.600.151.14-0.06
Revenue Per Share13.869.147.5911.6314.52
Net Income Per Share6.44-0.223.02-1.983.44
Tax Burden0.78-1.600.82-0.930.79
Interest Burden1.000.450.990.950.79
Research & Development to Revenue0.300.130.190.180.13
SG&A to Revenue0.340.470.400.360.19
Stock-Based Compensation to Revenue0.000.250.200.310.16
Income Quality0.40-24.070.95-4.131.38

Currency in USD